The cost of treating cancer patients with antineoplastic medications during inpatient hospital admission

Alexandra Foster
Butler University

David J. Reeves
Butler University, dreeves@butler.edu

Follow this and additional works at: https://digitalcommons.butler.edu/cophs_papers

Part of the Oncology Commons, and the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
https://digitalcommons.butler.edu/cophs_papers/200

This Conference Proceeding is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital Commons @ Butler University. It has been accepted for inclusion in Scholarship and Professional Work – COPHS by an authorized administrator of Digital Commons @ Butler University. For more information, please contact digitalscholarship@butler.edu.
Pharmacoeconomics/Outcomes

533. The cost of treating cancer patients with antineoplastic medications during inpatient hospital admission. Alexandra Foster, Pharm.D. Candidate; David Reeves, Pharm.D., BCOP; (1) College of Pharmacy and Health Sciences, Butler University (2) St. Vincent Indianapolis Hospital and College of Pharmacy and Health Sciences, Butler University

PURPOSE: Cancer treatment represents a substantial portion of health care costs and is projected to increase by twenty-seven percent from 2010 to 2020, with total costs reaching 158 billion dollars per year. Due to these projections, it is imperative for institutions to implement cost saving strategies, as well as maximize reimbursement. The objective of this study is to evaluate the cost and necessity of providing chemotherapy regimens in the inpatient setting and explore the savings associated with implementation of a policy defining the appropriate indications for the use of inpatient chemotherapy.

METHODS: A retrospective chart review of adult patients receiving inpatient chemotherapy during January, April, July, and October of 2010, 2012, and 2014 at St. Vincent Hospital in Indianapolis is in progress. Demographic data, chemotherapy regimens (cycle number, dosing, schedule, agents, and routes of administration), prior adverse effects, reasons for inpatient chemotherapy, and cost of chemotherapy regimens (average wholesale price) are being collected. Necessity of inpatient chemotherapy will be determined based on adherence to the available guidelines for inpatient chemotherapy. Institutional review board approval was received on August 27, 2013.

RESULTS: Records of 415 patients receiving chemotherapy during ten of the twelve intended months have been retrospectively reviewed. Data collection for July and October 2012 are currently in progress. Preliminary results indicate the annualized number of patients receiving chemotherapy in the inpatient setting decreased from 579 patients in 2010 to 381 patients in 2014, while the annualized number of patients admitted specifically for chemotherapy decreased from 327 patients in 2010 to 189 patients in 2014. Financial and statistical analysis will be conducted upon completion of data collection.

CONCLUSION: Preliminary data suggests the number of patients receiving inpatient chemotherapy and the number of patients admitted specifically for chemotherapy decreased after implementation of a policy in 2014 regarding appropriate inpatient chemotherapy use.

Pharmacogenomics/Pharmacogenetics

537. Effects of CYP2D6 genetic polymorphisms on the pharmacokinetics of tramadol and its active metabolite. Hye-Jin Lim, B.S., Dong-Hyun Kim, B.S., Young-Hoon Kim, B.S., Se-Hyung Kim, Ph.D.Candidate, Ji-Yeong Byeon, B.S., Sok-Yong Lee, Ph.D.; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

PURPOSE: Tramadol is a synthetic μ-receptor agonist used for the relief of moderate to severe acute and chronic pain. Tramadol is metabolized to O-demethyltramadol (ODT) metabolized in the liver. Also tramadol itself possesses serotonin and norepinephrine reuptake blocking activity. CYP2D6 is responsible for the metabolism of approximately 25% of clinically used drugs and especially CYP2D6*10 allele is accounted for 50% of CYP2D6 allele in Asian. We investigated the effects of CYP2D6*10 allele on the pharmacokinetics of tramadol and its active metabolite.

METHODS: Thirty healthy Korean volunteers with CYP2D6*wt/*wt, CYP2D6*wt/*10 (n = 10), CYP2D6*wt/*10 (n = 10) and CYP2D6*10/*10 (n = 10) were selected for this study. Each volunteer received a single oral dose of 100 mg tramadol after overnight fasting. Blood samples were collected up to 30 hour after drug intake, and plasma concentrations of tramadol and its metabolite were determined by using LC-MS/MS analytical system.

RESULTS: AUC_{\text{trat}} of tramadol in CYP2D6*10/*10 group was higher than those in CYP2D6*wt/*wt genotype group; 3237.3 ± 765.7 ng·hour/mL and 2146.4 ± 407.2 ng·hour/mL (p < 0.001). But C_{\text{max}} tramadol was not significantly different among three different groups. In terms of O-demethyltramadol (ODT), AUC_{\text{trat}} in CYP2D6*10/*10 group was lower than those in CYP2D6*wt/*wt genotype group; 882.7 ± 274.0 ng·hour·mL and 1173.9 ± 165.9 ng·hour·mL (p < 0.001).

CONCLUSIONS: In conclusion, CYP2D6*10 allele has significant effects on the pharmacokinetics of tramadol and its active metabolite.

538. Effects of CYP2C9*13 allele on the pharmacokinetics of Irbesartan. Hye-Jin Lim, B.S., Dong-Hyun Kim, B.S., Ji-Yeong Byeon, B.S., Young-Hoon Kim, B.S., Se-Hyung Kim, Ph.D. Candidate; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

PURPOSE: Irbesartan is an angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, and is used for the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Irbesartan is metabolized by polymorphic CYP2C9 to inactive metabolite. CYP2C9*13 allele show impaired activity towards a number of substrates both in vitro and in vivo. Unlike CYP2C9*3, which has been extensively studied in humans, clinical studies of CYP2C9*13 have been limited by the difficulty in finding subjects carrying this low-frequency allele. We evaluated the effect of CYP2C9*13 allele on the pharmacokinetics of irbesartan in healthy volunteers.

METHODS: In this study, we enrolled 1907 healthy Korean subjects and divided into four different groups according to CYP2C9